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Abstract
Background: Insulin resistance triggered by excess fat is a key pathogenic factor that promotes type 2 diabetes.
Understanding molecular mechanisms of insulin resistance may lead to the identification of a novel therapeutic
target for type 2 diabetes. AMPD1, an isoform of AMP deaminase (AMPD), is suggested to play roles in the regulation
of glucose metabolism through controlling AMP-activated protein kinase (AMPK) activation. We reported that the
diet-induced insulin resistance was improved in AMPD1-deficient mice compared to wild type mice. To further
delineate this observation, we studied changes of insulin signaling in skeletal muscle of wild type (WT) and
AMPD1-deficient mice.
Methods: Phosphorylation levels of kinases and expression levels of mTOR components were quantified by
immunoblotting using protein extracts from tissues. The interaction between mTOR and Raptor was determined
by immunoblotting of mTOR immunoprecipitates with anti-Raptor antibody. Gene expression was studied by
quantitative PCR using RNA extracted from tissues.
Results: Phosphorylation levels of AMPK, Akt and p70 S6 kinase in skeletal muscle were higher in AMPD1-deficient
mice compared to WT mice after high fat diet challenge, while they did not show such difference in normal chow diet.
Also, no significant changes in phosphorylation levels of AMPK, Akt or p70 S6 kinase were observed in liver and white
adipose tissue between WT and AMPD1-deficient mice. The expression levels of mTOR, Raptor and Rictor tended to be
increased by AMPD1 deficiency compared to WT after high fat diet challenge. AMPD1 deficiency increased
Raptor-bound mTOR in skeletal muscle compared to WT after high fat diet challenge. Gene expression of peroxisome
proliferator-activated receptor-γ coactivator 1α and β, downstream targets of p70 S6 kinase, in skeletal muscles was not
changed significantly by AMPD1 deficiency compared to the wild type after high fat diet challenge.
Conclusion: These data suggest that AMPD1 deficiency activates AMPK/Akt/mTORC1/p70 S6 kinase axis in skeletal muscle
after high fat diet challenge, but not in normal chow diet. These changes may contribute to improve insulin resistance.
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Background
Insulin resistance that is characterized by reduced sensi-
tivity and response to insulin action of insulin-sensitive
organs is an important pathogenic factor for type 2 dia-
betes triggered by excess nutrient intake, in addition to
impaired insulin secretion caused by pancreatic β cell
dysfunction [1]. Among insulin-sensitive organs, skeletal
muscle is a major contributor to glucose tolerance
through regulating glucose uptake by glucose transporter
[2]. Therefore, understanding the molecular mechanism
that regulates insulin sensitivity in skeletal muscle would
lead to the identification of novel therapeutic target for
type 2 diabetes.
Metabolic stress changes cellular adenine nucleotide
levels and resultantly modifies cellular response. AMP
deaminase (AMPD) catalyses the deamination of AMP
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into inosine monophosphate (IMP) and determines cel-
lular AMP levels [3]. Cellular AMP level is a crucial de-
terminant for the activation of AMP-activated protein
kinase (AMPK) that is a key regulator of energy, glucose
and lipid metabolism and possesses anti-diabetic prop-
erty [4]. Accordingly, AMPD is considered to participate
in the regulation of AMPK. AMPD has three isoforms
designated as AMPD1, 2 and 3. AMPD1 is highly select-
ively expressed in skeletal muscle, of which mutations
may be involved in human metabolic myopathy [3].
Variation of AMPD1 gene is reportedly associated with
higher insulin clearance in human [5]. A lower incidence
of type 2 diabetes in AMPD1 deficient human subjects
is also demonstrated [6]. Therefore, we have studied
roles of AMPD1 in the regulation of glucose metabolism
using AMPD1 deficient mice made by the gene targeting
[7,8]. We demonstrated that AMPD1 deficient mice
show augmented glucose tolerance and attenuated insu-
lin resistance under high fat diet feeding triggering insu-
lin resistance [8].
In this study, we investigated insulin signaling in
insulin-sensitive organs from control wild type C57BL6
mice and AMPD1-deficient mice fed with normal chow
and high fat diet in order to further analyze the under-
lying mechanism for augmented glucose tolerance and
attenuated insulin resistance induced by AMPD1 defi-
ciency under high fat diet feeding. We studied the acti-
vation of kinases that participate in insulin signaling by
assessing their auto-phosphorylation levels. Since we
demonstrated enhanced AMPK phosphorylation in skel-
etal muscle by AMPD1 deficiency, we tried to analyze
Akt phosphorylation and the activation of mammalian
mTOR complex1 (mTORC1), which is a crucial link of
AMPK and Akt in regards to insulin signaling. Also, we
investigated p70 S6 kinase [9] as the downstream target
of these molecules. Therefore, we studied AMPK/Akt/
mTORC1/p70 S6 kinase axis in skeletal muscle after
high fat diet challenge in AMPD1-deficient mice to show
the impact of AMPD1 on insulin resistance.
Methods
Animals
C57BL/6 control mice and AMPD1 deficient (Ampd1
−/−) mice generated as described previously [7,8] housed
in a controlled SPF environment with a 12-hour light–
dark cycle and constant temperature (25°C) at 5 weeks
old were fed with normal chow diet (CE-2; CLEA Japan,
Inc., Tokyo, Japan) or a high-fat diet (HFD32; CLEA
Japan, Inc.) with 60% fat calories for 12 weeks. Then,
mice were fasted for 17 hours and sacrificed under
anesthesia with isoflurane.
All animal experiments approved by the Committee on
Animal Research of National Cerebral and Cardiovascular
Center were performed according to the guidelines for the
protection of experimental animals of National Cerebral
and Cardiovascular Center.
Immunoblotting
Tissues were homogenized into RIPA buffer containing
10 mM Tris pH7.4, 1% NP40, 0.1% sodium deoxycho-
late, 0.1% SDS, 0.15 M NaCl, 1 mM EDTA, cOmplete
ULTRA protease inhibitor cocktail (Roche Diagnostics,
Mannheim, Germany) and PhosSTOP phosphatase in-
hibitor cocktail (Roche Diagnostics). After centrifuge,
the supernatant of the homogenate was collected and
used for protein determination with a BCA Protein
Assay Kit (Pierce, Rockford, IL, USA). The supernatant
was boiled with Laemmli sample buffer, resolved by one
dimensional SDS-PAGE and then electrophoretically
transferred to polyvinylidene difluoride membranes
using Trans-Blot Turbo System (Bio-Rad Laboratories
Inc., Hercules, CA, USA). The membranes were sub-
jected to immunoblotting as described previously with
different primary antibodies (anti-AMPKα antibody,
#2532; anti-phosphoAMPKα (Thr172) antibody, #2535;
anti-Akt antibody, #4691; anti-phospho Akt (Ser473)
antibody, #4060; anti-p70 S6 kinase antibody, #2708;
anti-phospho p70 S6 kinase (Thr389) antibody, #9234:
anti-mTOR antibody, #2983; anti-Raptor antibody,
#2280; anti-Rictor antibody, #2114; anti-α − tubulin anti-
body, #2125; Cell Signaling Technology, Danvers, MA,
USA) (8). Signals were developed with an ECL Prime kit
(GE Healthcare, Piscataway, NJ, USA) and detected
using LAS-1000 Luminescent Image Analyzer (FUJI-
FILM, Tokyo, Japan). Band intensity was quantified
using Image Reader LAS-1000 software (FUJIFILM).
Samples from five mice of each group were analyzed.
Immunoprecipitation
We immunoprecipitated mTOR following a previous re-
port [10]. Tissue was homogenized with a lysis buffer
containing 0.3% CHAPS. After centrifuge, the super-
natant was collected and used for protein determination
with a BCA Protein Assay Kit (Pierce). The input repre-
sented 5% of the lysate used for each immunoprecipita-
tion for the normalization with the levels of a
housekeeping gene product α-tubulin. Lysates were in-
cubated with anti-mTOR antibody (#2972, Cell Signaling
Technology) at 4°C for 1 hour followed by the incuba-
tion with Dynabeads Magnetic Beads (Life Technologies,
Carlsbad, CA, USA) at 4°C for another 1 hour. Beads
were washed with lysis buffer and immunoprecipitates
were eluted by boiling with Laemmli sample buffer.
RNA extraction and quantitative PCR
RNA was isolated from tissues with Isogen II following
the manufacturer’s protocol (Nippon gene, Tokyo,
Japan). cDNA synthesis was performed using 2 μg total
Tandelilin et al. BMC Endocrine Disorders    Page 2 of 8
RNA and SuperScript III following the manufacturer’s
protocol (Invitrogen, Carlsbad, CA, USA). Real-time
PCR products performed with Power SYBR Green Mas-
ter Mix (Life Technologies) were analyzed using an ABI
PRISM 7900 sequence detection system (Applied Biosys-
tems) and normalized with control β-actin mRNA levels.






Data are expressed as means ± SD. Data were analyzed
by parametric ANOVA followed by Tukey’s multiple
comparison test. We considered that P values smaller
than 0.05 were statistically significant.
Results
We investigated the activation of insulin signaling path-
ways in which AMPK, Akt and p70 S6 kinase participate
in insulin-sensitive tissues such as skeletal muscle, liver
and white adipose tissue. Since AMPK, Akt and p70 S6
kinase are activated by upstream kinases in response to
stimuli through auto-phosphorylation, we evaluated
their phosphorylation levels by immunoblotting.
Phosphorylation level of AMPK tended to elevate by
AMPD1 deficiency in mice fed with normal chow diet
(left panel, Figure 1). AMPK phosphorylation was sig-
nificantly enhanced by AMPD1 deficiency in mice fed
with high fat diet. Akt phosphorylation was also signifi-
cantly augmented by AMPD1 deficiency in mice fed
with high fat diet, but not with normal chow diet (mid-
dle panel, Figure 1). As a downstream of insulin signal-
ing, phosphorylation of p70 S6 kinase was significantly
augmented by AMPD1 deficiency in mice fed with high
fat diet, but not with normal chow diet (right panel,
Figure 1).
In liver, AMPK phosphorylation was not significantly
changed by AMPD1 deficiency either in normal chow
diet or under high fat diet challenge (left panel, Figure 2).
Akt phosphorylation showed no significant difference
between wild type and AMPD1-deficient mice both in
normal chow diet and under high fat diet challenge
(middle panel, Figure 2). In good accordance with
changes in phosphorylation levels of AMPK and Akt,
p70 S6 kinase phosphorylation was not significantly
changed by AMPD1 deficiency either in normal chow
diet or under high fat diet challenge (right panel,
Figure 2).
AMPK phosphorylation demonstrated no significant
difference between WT and AMPD1-deficient mice fed
with normal chow and high fat diet in subcutaneous
adipose tissue (upper left panel, Figure 3). Akt phosphor-
ylation tended to be lower, but not significant in
AMPD1-deficient subcutaneous adipose tissue com-
pared to control under normal chow condition or high
fat diet feeding (upper middle panel, Figure 3). Phos-
phorylated p70 S6 kinase levels also showed no signifi-
cant difference between WT and AMPD1-deficient mice
(upper right panel, Figure 3).
Phosphorylation levels of AMPK (lower left panel,
Figure 3), Akt (lower middle panel, Figure 3) and p70
S6 kinase (lower right panel, Figure 3) showed no
Figure 1 AMPD1 deficiency significantly augmented phosphorylation of AMPK, Akt and p70 S6 kinase after high fat diet challenge in
skeletal muscles. Protein extracts from gastrocnemius muscle of wild type and AMPD1 deficient mice fed with normal chow and high fat diet
were studied by immunoblotting for AMPK/phosphorylated AMPK (pAMPK), Akt/phosphorylated Akt (pAkt) and p70 S6 kinase/phosphorylated
p70 S6 kinase (pp70 S6kinase) (n = 5 for each group). The ratio of the band intensity for phosphorylated form to that of total form measured as
described in Methods was quantified and adjusted with that of α-tubulin. Representative immunoblot images are shown in upper panels. Data
shown in lower panels are mean ± SD expressed relative to that of WT mice fed with normal chow. *and **indicate p < 0.05 vs. WT mice fed with
high fat diet and AMPD1-deficient mice fed with normal chow, respectively.
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significant difference between WT and AMPD1-
deficient mice under normal chow condition and high
fat diet feeding in epididymal white adipose tissue that
is included in visceral adipose tissue.
These data suggest that AMPD1 deficiency signifi-
cantly enhances activation of AMPK, Akt and p70 S6
kinase in skeletal muscle under high fat diet, in contrast
to normal chow diet condition. AMPD1 deficiency
seems not to change activation of AMPK, Akt and p70
S6 kinase in liver or white adipose tissue including sub-
cutaneous and visceral adipose tissue under normal
chow and high fat diet. Differential regulation of AMPK/
Akt/p70 S6 kinase indicates that skeletal muscle is pri-
mary target of the deficiency of AMPD1 which exhibits
a highly selective expression in skeletal muscle.
mTOR integrates insulin signal mediated by AMPK
and Akt and transduces signal to downstream targets in-
cluding p70 S6 kinase through formation of mTORC1
with Raptor as a positive regulator and mTORC2 with
Rictor as a negative regulator [9,10]. Therefore, we com-
pared the expression of mTOR, Raptor and Rictor and
the formation of mTORC in skeletal muscle from WT
and AMPD1-deficient mice (Figure 4). Protein expres-
sion of mTOR, Raptor and Rictor showed no significant
difference between WT and AMPD1-deficient mice fed
with normal chow, while AMPD1 deficiency tended to
increase protein expression of mTOR, Raptor and Rictor
in skeletal muscle after high fat diet challenge compared
to control (Figure 4A). We quantified the amount of
mTORC1 as a positive regulator of mTOR signaling by
detecting mTOR-bound Raptor in mTOR immunopre-
cipitates from lysates of skeletal muscle (Figure 4B).
Since mTOR expression levels were changed by AMPD1
deficiency as shown in Figure 4A, we adjusted the band
intensity of mTOR-bound Raptor with that of a house-
keeping gene product α-tubulin detected in 5% protein
amount of the input lysates which were used for immu-
noprecipitation. mTOR-bound Raptor in skeletal muscle
showed no obvious difference between WT and
AMPD1-deficient mice fed with normal chow, while
AMPD1 deficiency significantly increased mTOR-
bound Raptor in skeletal muscle after high fat diet chal-
lenge compared to control. These data suggest that
AMPD1 deficiency induces the expression of mTORC
components and upregulates mTOR signaling by pro-
moting mTORC1 formation in skeletal muscle after
high fat diet feeding.
As the current study indicates that AMPK/Akt/
mTOR/p70 S6 kinase pathway is upregulated in skel-
etal muscle by AMPD1 deficiency under high fat diet
feeding, we studied gene expression of peroxisome
proliferator-activated receptor-γ coactivator-1 (PGC1)
α and β in skeletal muscle that are downstream targets
of mTOR/p70 S6 kinase pathway [11]. PGC1 com-
prises a family of transcription factor that regulates
cellular energy metabolism through mitochondria bio-
genesis and participates in the control of glucose and
lipid metabolism. mRNA expression of PGC1α and β
in skeletal muscle showed no significant difference be-
tween WT and AMPD1-deficient mice under normal
chow diet as well as high fat diet challenge (Figure 5).
These data suggest that AMPD1 deficiency induces
upregulated gene expression of downstream targets of
p70 S6 kinase in skeletal muscle after high fat diet
challenge which could contribute to attenuated insulin
resistance.
Figure 2 AMPD1 deficiency did not change phosphorylation levels of AMPK, Akt and p70 S6 kinase after high fat diet challenge in liver.
Protein extracts from liver of wild type and AMPD1 deficient mice fed with normal chow and high fat diet were studied by immunoblotting for AMPK/
phosphorylated AMPK (pAMPK), Akt/phosphorylated Akt (pAkt) and p70 S6 kinase/phosphorylated p70 S6 kinase (pp70 S6kinase) (n = 5 for
each group). The ratio of the band intensity for phosphorylated form to that of total form was quantified and adjusted with that of α-tubulin.
Representative immunoblot images are shown in upper panels. Data shown in lower panels are mean ± SD expressed relative to that of WT
mice fed with normal chow.
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Discussion
Insulin resistance defines a condition in which tissue
sensitivity to insulin action is decreased due to inhibited
intracellular insulin signaling [1,2]. Obesity induced by
excess nutrient intake is a major cause of insulin resist-
ance, which leads to the onset and development of type
2 diabetes in cooperation with impaired pancreatic β cell
function [1,2]. Therefore, insulin resistance has been
paid a lot of attention as a therapeutic target for type 2
diabetes.
Skeletal muscle plays major roles in glucose uptake
through glucose transporter in response to insulin action
[2]. Accordingly, insulin resistance in skeletal muscle re-
sults in attenuated glucose tolerance. We showed in the
previous report that the deficiency of AMPD1 which is
highly selectively expressed in skeletal muscle attenuates
insulin resistance induced by high fat diet feeding in
C57BL6 mice that is an experimental model for insulin
resistance [12]. Admyre et al. recently published that
AMPD1 deficiency did not improve insulin resistance in
C57BL6 mice [13]. They demonstrated that AMPD1 de-
ficiency did not significantly augment, but at the very
least did not attenuate glucose tolerance compared to
control. The difference from our previous results may be
due to the difference in experimental condition includ-
ing the contents of feeding (5.08 kcal/g in our previous
study vs. 5.24 kcal/g in Reference 13) and fasting time
before glucose tolerance test (17 hours in our previous
study vs. 4 hours in Reference 13).
To further clarify the underlying mechanism that con-
tribute to the attenuated insulin resistance by AMPD1
deficiency in our experimental model, we studied insulin
signaling in the present study and demonstrated that
AMPD1 deficiency upregulates AMPK/Akt/mTOR/p70
S6 kinase pathway compared to control in skeletal
muscle, but not in liver or white adipose tissue, among
Figure 3 AMPD1 deficiency did not change phosphorylation levels of AMPK, Akt and p70 S6 kinase after high fat diet challenge in
white adipose tissue. Protein extracts from subcutaneous and visceral adipose tissue of wild type and AMPD1 deficient mice fed with normal
chow and high fat diet were studied by immunoblotting for AMPK/phosphorylated AMPK (pAMPK), Akt/phosphorylated Akt (pAkt) and p70 S6
kinase/phosphorylated p70 S6 kinase (pp70 S6kinase) (n = 5 for each group). The ratio of the band intensity for phosphorylated form to that of
total form was quantified and adjusted with that of α-tubulin. Representative immunoblot images are shown in upper panels. Data shown in
lower panels are mean ± SD expressed relative to that of WT mice fed with normal chow.
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Figure 4 Promoted mTORC1 formation in skeletal muscle after high fat diet feeding by AMPD1 deficiency. (A) Protein extracts from
gastrocnemius muscle of wild type and AMPD1 deficient mice fed with normal chow and high fat diet were subjected to immunoblotting for
mTOR, Raptor and Rictor (n = 5 for each group). The band intensity was quantified and adjusted with that of α-tubulin. Representative immunoblot
images are shown in upper panels. Data shown in lower panels are mean ± SD expressed relative to that of WT mice fed with normal chow. (B)mTOR
immunoprecipitates from gastrocnemius muscle were analyzed by immunoblotting with anti-Raptor antibody. The band intensity of mTOR-bound
Raptor in immunoprecipitates was adjusted with that of α-tubulin in the input lysates used for immunoprecipitation. Representative immunoblot
images of Raptor in mTOR immunoporecipitates and α-tubulin in the input lysates are shown in upper panels. Data shown in lower panel are mean ±
SD expressed relative to that of WT mice fed with normal chow (n = 5 for each group). *indicates p < 0.05 vs. WT mice fed with high fat diet.
Figure 5 Effects of AMPD1 deficiency on gene expression of downstream targets of p70 S6 kinase in skeletal muscle. mRNA expression
of PGC1α and β was quantified by real-time PCR using RNA extracted from gastrocnemius muscle of WT and AMPD1 deficient mice fed with
normal chow and high fat diet (n = 5 for each group). The mRNA expression levels were normalized with respect to β-actin expression. Data
shown are mean ± SD expressed relative to that of WT mice fed with normal chow.
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insulin-sensitive organs under high fat diet feeding. In
accordance with this result, gene expression of PGC1 α
and β that are downstream targets of p70 S6 kinase
tended to increase in skeletal muscle [11]. Since these
results suggest that AMPD1 deficiency inhibits the at-
tenuation of insulin signaling in skeletal muscle under
high fat diet feeding, they support the notion that
AMPD1 deficiency attenuates insulin resistance induced
by high fat diet feeding.
The protein complex mTORC1 and 2 that is com-
posed of a kinase mTOR and associated proteins trans-
duces signals of insulin and nutrients to a variety of
downstream targets and serves as a central regulator of
metabolism [14]. In this study, we showed that AMPD1
deficiency tended to increase the expression of mTOR
and Raptor and promoted formation of mTORC1 in
skeletal muscle after high fat diet challenge. In accord-
ance with increased mTORC1 levels, a downstream tar-
get p70 S6 kinase showed enhanced activation by
AMPD1 deficiency. Therefore, we suggest mTORC1-p70
S6 kinase pathway as a novel target of AMPD1 in skel-
etal muscle under high fat diet feeding. Further studies
are needed to clarify the molecular mechanisms how
AMPD1 levels and concomitantly modified cellular ad-
enine nucleotide levels regulate the expression levels of
mTOR and related molecules and the formation of
mTORC1. Studies using in vitro culture system in com-
bination with overexpression and knockdown of Ampd1
gene and pharmacological intervention using AMP mi-
metics [15] could be useful for this purpose. We are cur-
rently studying in this context.
Although AMPD1 deficiency seems not to change
gene expression of PGC1α and β, downstream targets of
p70 S6 kinase that regulate mitochondria biogenesis for
energy expenditure and glucose uptake in skeletal
muscle [11], AMPD1 deficiency may modify the expres-
sion and function of other downstream targets for p70
S6 kinase, which include the factors that potentially con-
tribute to insulin sensitivity regulation in skeletal muscle
and the soluble factors including myokines that partici-
pate in inter-organ communication and regulate glucose
metabolism in remote target organs [16]. Comprehen-
sive analysis of transcriptome and proteome for skeletal
muscle in combination with the comparison of the
effects of diet type and AMPD1 deficiency are to be ex-
plored in the future research.
Conclusion
We demonstrated that AMPD1 deficiency enhances acti-
vation of AMPK/Akt/mTORC1/p70 S6 kinase pathway
in skeletal muscle under high fat diet feeding that could
potentially contribute to attenuated insulin resistance, in
accordance with our previous report using an in vivo ex-
perimental model [8]. Our current study provides novel
evidence that mTORC1, a key regulator of insulin signal
and cellular metabolism, and p70 S6 kinase are targets
of AMPD1 in skeletal muscle under metabolic stress in-
duced by high fat diet challenge.
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